Inhibition of Cultured Human Tumor Cell Oxygen Utilization by Chlorpromazine

  • M. A. Shenoy
  • J. E. Biaglow
  • M. E. Varnes
  • F. W. Hetzel
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 159)


Chlorpromazine hydrochloride (CPZ) a widely used tranquilizer was earlier shown to preferentially sensitize hypoxic bacterial cells to 60Co gamma rays (Shenoy, George, Singh & Ayengar, 1975). CPZ was also observed to be toxic towards hypoxic cells (Shenoy & Singh, 1978) and this hypoxic cytotoxicity was found to be dependent on temperature. When tested in murine tumors, the drug sensitized Sarcoma 180A (Shenoy & Singh, 1980) as well as fibrosarcoma (George Srinivasan & Singh, 1980) to x-rays. A marked chemotherapeutic effect of CPZ was evident in Sarcoma 180A (Shenoy & Singh, 1980) and this effect was more pronounced in clamped tumors (George et al., 1980), indicating the effectiveness of the drug when cells were under acute hypoxia.


Hypoxic Cell Ehrlich Ascites Tumor Chlorpromazine Hydrochloride NPSH Level Cellular OXygen Consumption 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Akera, T. and Brody, T. M. (1970) Mol. Pharmacol. 6, 557.PubMedGoogle Scholar
  2. 2.
    Biaglow, J. E. (1980) Pharmacol. and Therapeutics, 10, 283.CrossRefGoogle Scholar
  3. 3.
    Biaglow, J. E. (1981) Radiat. Research 86, 212.CrossRefGoogle Scholar
  4. 4.
    Biaglow, J. E. and Durand, R. E. (1976) Radiat. Research 65, 529.CrossRefGoogle Scholar
  5. 5.
    Biaglow, J. E., Greenstock, C. L. and Durand, R. E. (1978) Brit. Jour. Cancer, Suppl. III, 37, 145.Google Scholar
  6. 6.
    Biaglow, J. E., Jacobson, B., Greenstock, C. L. and Raleigh, J. A. (1977) Mol. Pharmacol. 13, 262.Google Scholar
  7. 7.
    Biaglow, J. E., Jacobson, B. and Nygaard, O. F. (1973) Cancer Res. 37, 3306.Google Scholar
  8. 8.
    Biaglow, J. E. and Nygaard, O. F. (1973) Biochem, Biophys. Res. Commun. 53, 874.CrossRefGoogle Scholar
  9. 9.
    Forrest, I. S. and Green, D. F. (1972) Jour. Forensic, Sc. 17, 592.Google Scholar
  10. 10.
    George, K. C., Srinivasan, V. T. and Singh, B. B. (1980) Int. Jour. Radiat. Biol. 38, 661.CrossRefGoogle Scholar
  11. 11.
    Shenoy, M. A., George, K. C., Singh, B. B. and Gopal-Ayengar, A. R. (1975) Int. Jour. Radiat. Biol. 28, 519.CrossRefGoogle Scholar
  12. 12.
    Shenoy, M. A, and Gopalakrishna, K. (1978) Int. Jour. Radiat. Biol. 33, 587.CrossRefGoogle Scholar
  13. 13.
    Shenoy, M. A. and Singh, B. B. (1978) Int. Jour. Radiat. Biol. 34, 595.CrossRefGoogle Scholar
  14. 14.
    Shenoy, M. A. and Singh, B. B. (1979) Sixth International Congress of Radiation Research, Tokyo (Japan), Abstract: A-27–5, p. 99.Google Scholar
  15. 15.
    Shenoy, M. A. and Singh, B. B., (1980) Ind. Jour. Exptl. Biol. 18, 791.Google Scholar
  16. 16.
    Varnes, M. E., Biaglow, J. E., Koch, C. J. and Hall, E. J. (1980) In “Radiation Sensitizers - Their Use in Clinical Management of Cancer” (ed. L. Brady), Masson Publ. USA, p. 121.Google Scholar
  17. 17.
    Yau, T. M. (1979) Radiat. Research 80, 523.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • M. A. Shenoy
    • 1
    • 2
  • J. E. Biaglow
    • 1
    • 2
  • M. E. Varnes
    • 1
    • 2
  • F. W. Hetzel
    • 1
    • 2
  1. 1.Division of Radiation Biology — Radiobiological Sciences & Hyperthermia DivisionHenry Ford HospitalDetroitUSA
  2. 2.Case Western Reserve UniversityClevelandUSA

Personalised recommendations